Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lorukafusp alfa
- Development stage
- Phase 2
- Lead developer
- Apeiron Biologics
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Lorukafusp alfa is an intravenously administered immunocytokine, a recombinant fusion protein comprising a humanized 14.18 anti-GD2 monoclonal antibody linked to interleukin-2 (IL-2). Its mechanism of action involves targeting disialoganglioside GD2 on the surface of tumor cells, leading to antibody-dependent cell cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Additionally, it activates natural killer (NK) cells and T cells through binding to the interleukin-2 receptor. This dual mechanism contributes to its anti-tumor activity. The drug has been developed by several entities including Apeiron Biologics, Merck KGaA, National Cancer Institute (USA), University of Wisconsin-Madison, Lexigen Pharmaceuticals, and Bristol Myers Squibb Co.
- Other names
- Monoclonal antibody ch14.18 interleukin-2 fusion protein
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)GD2
Beyond the preview
Go deeper on Lorukafusp alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lorukafusp alfa.